GUEST COLUMNISTS

• The Much-Feared FDA Form 483

  Dr. Robert Califf explains that FDA Form 483 is often misunderstood as a final judgment, when it is actually an initial notice of potential issues found during inspections. He argues the form should be seen as a tool for quality improvement, not a proxy for overall performance, and he calls for more efficient processes to reduce unnecessary anxiety and delays.

• Unlocking Biopharma Innovation With Real-World Evidence

  Discover how how federated data networks, platform aggregators, and collaborative partnerships have evolved to meet the data demands of modern product development, regulatory strategy, and commercial success.

• Bayesian Digital Twins Show Potential For Predicting Prognosis And Treatment Response

  Learn how Bayesian digital twins are trained, validated, and trusted in clinical settings and explore the potential for integrating these models into interventional trials.

• Bridging Language And Medicine: Best Practices In French Regulatory Medical Writing

  Poor translations are not just clunky. They can be risky. Medical-linguistic consultant Farah Ayadi, PharmD, explains its implications for safety, regulatory submissions, and downstream operational or financial outcomes.

• Research Center Layout Helps Lower Barriers To Cross-Industry Collaboration

  Discover how one research center, uniquely built for collaboration, enables the collection and analysis of high-quality specimens and data that will fuel both current and future research collaborations.

• Elsa's AI Model Migration: Technical, Compliance, And Regulatory Risks For Sponsors (Part 2)

  In the second part of their series on Elsa AI model migration, Kimberly Chew, Esq., and Michael Yang, Esq., analyze the risks to compliance and data residency, as well as the integrity of the regulatory record.

• Site Staffing On The Upswing, But Still A Challenge

  In this final article of the series, Jimmy Bechtel and Ken Getz discuss how workforce pressures have shaped site performance and what’s being done to strengthen site staff retention and career growth.

• From Real-World Data To Real-World Impact: Building The Evidence Capability Pharma Actually Needs

  Learn how companies that treat RWE as an operational capability will be better positioned to design more efficient trials, accelerate therapy adoption, strengthen payer negotiations, and demonstrate value across the healthcare ecosystem.